Literature DB >> 32311740

Medication for Opioid Use Disorder: A National Survey of Primary Care Physicians.

Emma E McGinty1, Elizabeth M Stone1, Alene Kennedy-Hendricks1, Marcus A Bachhuber2, Colleen L Barry1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32311740      PMCID： PMC8171002          DOI： 10.7326/M19-3975

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  2 in total

1.  Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.

Authors:  Jeffrey H Samet; Michael Botticelli; Monica Bharel
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

2.  Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.

Authors:  Kevin Fiscella; Sarah E Wakeman; Leo Beletsky
Journal:  JAMA Psychiatry       Date:  2019-03-01       Impact factor: 21.596
  2 in total
  13 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.

Authors:  Cindy Xinxin Du; Julia Shi; Jeanette M Tetrault; Lynn M Madden; Declan T Barry
Journal:  Fam Pract       Date:  2022-03-24       Impact factor: 2.267

3.  Opioid use disorder treatment in rural settings: The primary care perspective.

Authors:  Valerie S Harder; Andrea C Villanti; Sarah H Heil; M Lindsey Smith; Diann E Gaalema; Marjorie C Meyer; Nathaniel H Schafrick; Stacey C Sigmon
Journal:  Prev Med       Date:  2021-08-16       Impact factor: 4.018

4.  Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine.

Authors:  Mark Katz Meiselbach; Coleman Drake; Brendan Saloner; Jane M Zhu; Bradley D Stein; Daniel Polsky
Journal:  Health Aff (Millwood)       Date:  2022-06       Impact factor: 9.048

5.  Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.

Authors:  Alene Kennedy-Hendricks; Colleen L Barry; Elizabeth Stone; Marcus A Bachhuber; Emma E McGinty
Journal:  Drug Alcohol Depend       Date:  2020-08-06       Impact factor: 4.492

6.  The role of stigma in U.S. primary care physicians' treatment of opioid use disorder.

Authors:  Elizabeth M Stone; Alene Kennedy-Hendricks; Colleen L Barry; Marcus A Bachhuber; Emma E McGinty
Journal:  Drug Alcohol Depend       Date:  2021-02-16       Impact factor: 4.492

7.  Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.

Authors:  Suzan Iloglu; Paul J Joudrey; Emily A Wang; Thomas A Thornhill; Gregg Gonsalves
Journal:  Drug Alcohol Depend       Date:  2021-01-19       Impact factor: 4.492

8.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

9.  Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.

Authors:  Mara A G Hollander; Chung-Chou H Chang; Antoine B Douaihy; Eric Hulsey; Julie M Donohue
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

10.  Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.

Authors:  E Jennifer Edelman; Geliang Gan; James Dziura; Denise Esserman; Kenneth L Morford; Elizabeth Porter; Philip A Chan; Deborah H Cornman; Benjamin J Oldfield; Jessica E Yager; Srinivas B Muvvala; David A Fiellin
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.